425 related articles for article (PubMed ID: 19808131)
1. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
Ebers GC; Reder AT; Traboulsee A; Li D; Langdon D; Goodin DS; Wolf C; Beckmann K; Konieczny A;
Clin Ther; 2009 Aug; 31(8):1724-36. PubMed ID: 19808131
[TBL] [Abstract][Full Text] [Related]
2. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
5. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
[TBL] [Abstract][Full Text] [Related]
6. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
7. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
Cohen BA; Rivera VM
Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658
[TBL] [Abstract][Full Text] [Related]
8. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
Bermel RA; Weinstock-Guttman B; Bourdette D; Foulds P; You X; Rudick RA
Mult Scler; 2010 May; 16(5):588-96. PubMed ID: 20167591
[TBL] [Abstract][Full Text] [Related]
9. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
10. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
11. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
[TBL] [Abstract][Full Text] [Related]
12. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.
Patti F; Pappalardo A; Florio C; Politi G; Fiorilla T; Reggio E; Reggio A
Acta Neurol Scand; 2006 Apr; 113(4):241-7. PubMed ID: 16542163
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
[TBL] [Abstract][Full Text] [Related]
14. Defining interferon beta response status in multiple sclerosis patients.
Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
16. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
17. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
Río J; Nos C; Tintoré M; Téllez N; Galán I; Pelayo R; Comabella M; Montalban X
Ann Neurol; 2006 Feb; 59(2):344-52. PubMed ID: 16437558
[TBL] [Abstract][Full Text] [Related]
18. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
Boz C; Oger J; Gibbs E; Grossberg SE;
Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
[TBL] [Abstract][Full Text] [Related]
19. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Reder AT; Ebers GC; Traboulsee A; Li D; Langdon D; Goodin DS; Bogumil T; Beckmann K; Konieczny A;
Neurology; 2010 Jun; 74(23):1877-85. PubMed ID: 20530324
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
Murray TJ
Curr Med Res Opin; 2004 Jan; 20(1):25-30. PubMed ID: 14741068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
